Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 827-833

  Munzel, Ullrich ^a   Marschall, K ^a   Fyrnys, B ^b   Wedel, M ^b  

^a Viatris Inc   (Germany)

^b Sofotec   (Germany)

Author keywords

Budesonide; Dry powder inhaler; Fine particle dose; Lung deposition; Variability

Indexed keywords

BUDESONIDE;

ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; DEVICE; DRY POWDER; FLOW RATE; HUMAN; IN VIVO STUDY; INHALATION; MULTIPLE DRUG DOSE; PARTICLE SIZE; PATIENT COMPLIANCE; POWDER INHALER; QUALITY CONTROL; RELIABILITY;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS;

EID: 21244494833     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46241     Document Type: Article

References (33)

1. Barnes PJ. The size of the problem of managing asthma. Respir Med 2004;98(Suppl B):S4-8
2. Newman SP. Drug delivery to the lungs from dry powder inhalers. Curr Opin Pulm Med 2003;9(Suppl 1):S17-20
3. Clark AR. Medical aerosol inhalers: past, present, and future. Aerosol Sci Technol 1995;22:374-91
4. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 1994;102:127-32
5. Kohler D. Novolizer®: the new technology for the management of asthma therapy. Curr Opin Pulm Med 2003;9(Suppl 1):S11-6
6. Fyrnys B, Stang N, Wolf-Heuss E. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Curr Opin Pulm Med 2001;7(Suppl 1):S7-11
7. Everard ML, Devadason SG, Le Souef PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997;91:624-8
8. Newman SP. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs? Br J Clin Pharmacol 2000;49:529-37
9. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124:360-6
10. Dunbar C, Scheuch G, Sommerer K, DeLong M, Verma A, Batycky R. In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. Int J Pharm 2002;245:179-89
11. Duddu SP, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm Res 2002;19(5):689-95
12. Committee for Proprietary Medicinal Products (CPMP). Points to consider on the requirements for clinical documentation for orally inhaled products (OIP). CPMP/EWP/4151/00, London, 22 April 2004
13. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293-304
14. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988;5(8):506-8
15. Siddiqui MAA, Plosker GL. The Novolizer®. A multidose dry powder inhaler. Treat Respir Med 2005;4(1):63-9
16. Moller M, Fritsche D, Rivera D, Libertus H. Improvement of asthma therapy by a novel budesonide multidose dry powder inhaler. Arzneim-Forsch/Drug Res 2003;53(8):562-7
17. Berner B, Fyrnys B, de Boer AH. ASTA Medica's innovative multidose dry powder inhaler: operation and performance. In: Proceedings of the 46th annual congress of APV/APGI 2000, April 3-6, Berlin, Germany. p. 781-82
18. de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Comparative in vitro performance evaluation of the Novopulmon® 200 Novolizer® and Budesonide-ratiopharm® Jethaler: two novel budesonide dry powder inhalers. Pharmazie 2004;59(9):692-9
19. Richter K. Successful use of DPI systems in asthmatic patients - key parameters. Respir Med 2004;98(Suppl B):S22-7
20. Meakin BJ, Ganderton D, Panza I, Ventura P. The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med 1998;11(3):143-52
21. Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998;92:105-10
22. Malton A, Sumby BS, Dandiker Y. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbuhaler inhalers. J Pharm Med 1996;6:35-48
23. Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004;17(1):25-32
24. Richter K, Ellers-Lenz B, Nguyen DT, Munzel U, Maus J, Magnussen H. Severe asthmatic patients generate significantly different peak inspiratory flows (PIF) through two different dry powder inhalers (DPI). Eur Resp J 2004;24(Suppl 48):308s [abstract P1973]
25. Von Berg A, Groß I, Leupold W, et al. Asthmatic children generate significantly different peak inspiratory flow rates (PIFR) through two different dry powder inhalers (DPI). Eur Resp J 2003;22(Suppl 45):494s [abstract P3101]
26. Richter K, Ellers-Lenz B, Nguyen DT, Munzel U, Maus J, Magnussen H. COPD patients generate significantly different peak inspiratory flows (PIF) through two different dry powder inhalers (DPI). Eur Resp J 2004;24(Suppl 48):88s [abstract P651]
27. Newman SP, Hirst PH, Pitcairn GR. Scintigraphic evaluation of lung deposition with a novel inhaler device. Curr Opin Pulm Med 2001;7(Suppl 1):S12-4
28. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000;16:178-83
29. Pitcairn GR, Lankinen T, Seppälä OP, Newman SP. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J Aerosol Med 2000;13(2):97-104
30. Chow SC, Liu JP. The assessment of inter- and intra-subject variabilities. In: Design and analysis of bioavailability and bioequivalence studies. New York, Basel, Hong Kong: Marcel Dekker, Inc.; 1992. p. 186-216
31. Ganderton D. General factors influencing drug delivery to the lung. Respir Med 1997;91(Suppl A):13-6
32. Vogelberger C, Kremer HJ, Ellers-Lenz B, et al. Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer®. Respir Med 2004;98(10):924-31
33. Szefler SJ, Martin RJ, Sharp King T, et al., for the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109(3):410-18